MediciNova (MNOV) Projected to Post Earnings on Thursday

MediciNova (NASDAQ:MNOV) is projected to issue its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to post earnings of ($0.06) per share and revenue of $0.05 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

MediciNova (NASDAQ:MNOV) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. The company had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.07 million. MediciNova had a negative net margin of 1,168.70% and a negative return on equity of 26.51%. On average, analysts expect MediciNova to post ($0.25) EPS for the current fiscal year and ($0.51) EPS for the next fiscal year.

MediciNova Stock Performance

MediciNova stock opened at $1.40 on Wednesday. The business has a fifty day moving average of $1.79 and a two-hundred day moving average of $1.51. MediciNova has a twelve month low of $1.22 and a twelve month high of $3.90.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on MNOV. Roth Capital started coverage on MediciNova in a report on Thursday, September 17th. They issued a “buy” rating and a $6.00 price target on the stock. HC Wainwright restated a “buy” rating on shares of MediciNova in a research note on Tuesday, September 29th. Finally, Weiss Ratings upgraded MediciNova from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $7.75.

Insider Buying and Selling at MediciNova

In other news, major shareholder 3D Investment Partners Pte. Lt sold 640,000 shares of MediciNova stock in a transaction that occurred on Friday, September 25th. The shares were sold at an average price of $2.70, for a total value of $1,728,000.00. Following the transaction, the insider owned 4,862,047 shares of the company’s stock, valued at $13,127,526.90. The trade was a 11.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 14.00% of the company’s stock.

MediciNova Company Profile

MediciNova, Inc. (NASDAQ: MNOV) is a clinical-stage biopharmaceutical company based in San Diego, California. The company develops small-molecule therapies for diseases with significant unmet medical needs, with a primary focus on neurological, neurodegenerative, and other serious medical conditions. Its lead development program is MN-166, also known as ibudilast, an orally administered compound with anti-inflammatory and neuroprotective properties. MediciNova has evaluated ibudilast in clinical studies for conditions including progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance use disorders.